ArticleBlood2019
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 2 pooled it
22.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
164 citing papers in PubMed, 2 syntheses or guidelines pooled it, 269 citations in OpenAlex.
- A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.Frontiers in immunology · 2022Pooled it
- Trial
- Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.Nature medicine · 2024Trial
- Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.Blood · 2023Trial
- Article
- From molecular pathogenesis to novel Therapeutic approaches - a review of recent advances in the treatment of peripheral T cell Lymphomas.Biomarker research · 2026Review
- Secondary peripheral T-cell lymphoma in a patient with DLBCL harboringJournal for immunotherapy of cancer · 2026Article
- Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.Blood advances · 2026Observational
- Genome-epigenome crosstalk in T-cell lymphomas: from maps to mechanisms.International journal of hematology · 2026Review
- GATA3-positivity and T follicular helper phenotype in transformed mycosis fungoides with leukemic involvement and prominent folliculotropism: a case report.Frontiers in oncology · 2026Article
- XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis.Cell communication and signaling : CCS · 2025Article
- Epstein-barr virus-encoded small RNA incorporated prognostic model enables precision risk stratification and guides treatment decisions in peripheral t-cell lymphoma: a multicenter retrospective cohort.Annals of hematology · 2025Article
- CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas.Blood cancer journal · 2025Article
- Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.Journal of personalized medicine · 2025Review
- Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.Science advances · 2025Article
- Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study.Cell communication and signaling : CCS · 2025Article
- Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma.American journal of hematology · 2025Article
- Epidemiology of mature T-cell and NK-cell neoplasms: east and west.The Lancet regional health. Western Pacific · 2025Review
- Peripheral T-cell lymphoma with central nervous system involvement and elevated interleukin-10 levels in the cerebrospinal fluid: A case report.Precision radiation oncology · 2025Article
104 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 19 institutions in 10 countries.
Tayla B HeavicanPathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Alyssa BouskaPathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Jiayu YuPathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Waseem LonePathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Catalina AmadorPathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Qiang GongDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Weiwei ZhangPathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Yuping LiDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Bhavana J DavePathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Maarja-Liisa NairismägiDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
Timothy C GreinerPathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Julie VoseDivision of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE.
Dennis D WeisenburgerDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Cynthia LachelDivision of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE.
Chao WangPathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Kai FuPathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Jadd M StevensHuman Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE.
Soon Thye LimDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
Choon Kiat OngDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
Randy D GascoyneCenter for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.
Edoardo MissiagliaInstitute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.ORCID 0000-0001-9221-0117
Francois LemonnierDépartement de Pathologie, Université Paris-Est, Hôpital Henri-Mondor, INSERM U955, Créteil, France.
Corinne HaiounDépartement de Pathologie, Université Paris-Est, Hôpital Henri-Mondor, INSERM U955, Créteil, France.
Sylvia HartmannSenckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany.
Martin Bjerregård PedersenDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Maria Antonella LaginestraEuropean Institute of Oncology, Milan/Bologna University School of Medicine, Bologna, Italy.
Ryan A WilcoxDepartment of Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, MI.
Bin Tean TehDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
Noriaki YoshidaDepartment of Pathology, Kurume University School of Medicine, Fukuoka, Japan.
Koichi OhshimaDepartment of Pathology, Kurume University School of Medicine, Fukuoka, Japan.
Masao SetoDepartment of Pathology, Kurume University School of Medicine, Fukuoka, Japan.
Andreas RosenwaldInstitute of Pathology, University of Wuerzburg and Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany.
German OttDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Elias CampoHematopathology Unit, Hospital Clinic, Barcelona, Spain.
Lisa M RimszaDepartment of Pathology, University of Arizona, Tucson, AZ.
Elaine S JaffeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Rita M BrazielOregon Health Sciences Center, Portland, OR.
Francesco d'AmoreDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Giorgio InghiramiDepartment of Pathology and NYU Cancer Center, New York University School of Medicine, New York, NY.
Francesco BertoniUniversità della Svizzera Italiana, Istituto Oncologico di Ricerca, Bellinzona, Switzerland; and.ORCID 0000-0001-5637-8983
Laurence de LevalInstitute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
Philippe GaulardDépartement de Pathologie, Université Paris-Est, Hôpital Henri-Mondor, INSERM U955, Créteil, France.
Louis M StaudtMetabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Timothy W McKeithanDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Stefano PileriEuropean Institute of Oncology, Milan/Bologna University School of Medicine, Bologna, Italy.
Wing C ChanDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Javeed IqbalPathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
University of Nebraska Medical Center · USCity Of Hope National Medical Center · USNational Cancer Centre Singapore · SGInserm · FRKurume University · JPAarhus University Hospital · DKEuropean Institute of Oncology · ITNational Institutes of Health · USUniversity of Lausanne · CHBC Cancer Agency · CAComprehensive Cancer Center Mainfranken · DEGoethe University Frankfurt · DEHospital Clínic de Barcelona · ESNew York University · USOregon Health & Science University · USRobert Bosch Hospital · DEUniversità della Svizzera italiana · CHUniversity of Arizona · USUniversity of Michigan · US
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3MUNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Heather Colleen Jensen-Smith · 2012 to 2026
$59.2MUNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Apar Kishor Ganti · 1985 to 2026
$55.0MZINC FINGER-INSPIRED FLUORESCENT CHEMOSENSORSP20RR016469 · NCRR · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI TURPEN, JAMES B · 2001 to 2011
$36.2MTransplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI FORMAN, STEPHEN J, KWAK, LARRY W · 2004 to 2022
$35.5MMolecular diagnosis and outcome prediction in lymphomaZIABC011006 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2009 to 2025
$21.0MTRANSGENIC EXPRESSION ANALYSIS OF MIRNA-144P20RR018788 · NCRR · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI NYSTUEN, ARNE M · 2003 to 2011
$16.5MPreclinical Models and Therapeutics CoreP01CA229100 · NCI · MAYO CLINIC ARIZONA · PI INGHIRAMI, GIORGIO · 2018 to 2022
$10.2MThe Molecular Biology of Neurosurgery SystemsP20GM103471 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SMITH, SHELLEY D · 2012 to 2013
$4.1MMolecular Diagnosis and Prognosis in Aggressive LymphomaU01CA157581 · NCI · UNIVERSITY OF ARIZONA · PI RIMSZA, LISA · 2011 to 2015
$3.1MUT M.D. Anderson Cancer Center Lymphoma SPOREP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2009 to 2011
$1.5MUNMC SIG Supporting Next-generation DNA Sequencing TechnologyS10RR027754 · NCRR · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI EUDY, JAMES · 2010 to 2010
$500kNCI NIH HHS P01 CA229100NCI NIH HHS P30 CA033572NCI NIH HHS P30 CA036727NCI NIH HHS P50 CA107399NCI NIH HHS P50 CA136411NCI NIH HHS U01 CA157581NCI NIH HHS UH2 CA206127NCRR NIH HHS P20 RR016469NCRR NIH HHS P20 RR018788NCRR NIH HHS S10 RR027754NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P20 GM103471
Abstract
Peripheral T-cell lymphoma (PTCL) is a group of complex clinicopathological entities, often associated with an aggressive clinical course. Angioimmunoblastic T-cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS) are the 2 most frequent categories, accounting for >50% of PTCLs. Gene expression profiling (GEP) defined molecular signatures for AITL and delineated biological and prognostic subgroups within PTCL-NOS (PTCL-GATA3 and PTCL-TBX21). Genomic copy number (CN) analysis and targeted sequencing of these molecular subgroups revealed unique CN abnormalities (CNAs) and oncogenic pathways, indicating distinct oncogenic evolution. PTCL-GATA3 exhibited greater genomic complexity that was characterized by frequent loss or mutation of tumor suppressor genes targeting the
Indexed as
DNA Copy Number VariationsOncogenesFemaleGATA3 Transcription FactorGene Expression ProfilingHumansImmunoblastic LymphadenopathyLymphoma, T-Cell, PeripheralMaleMutationT-bet Transcription FactorT-Box Domain ProteinsGATA3 protein, humanGATA3 Transcription FactorT-bet Transcription FactorT-Box Domain Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.